Evidence has accumulated to show that mucosal healing can alter the course of Crohn's disease. New results from the EXTEND trial clearly demonstrate that adalimumab is able to induce and maintain mucosal healing in Crohn's disease and has the potential for disease modification.
|Titolo:||IBD Mucosal healing-EXTENDing our knowledge in Crohn's disease|
|Data di pubblicazione:||2012|
|Appare nelle tipologie:||1.1 Articolo in rivista|